ATF4 and chronic myelogenous leukemia, BCR-ABL1 positive: The oligomycin-induced ATF4 upregulation in the CML cell lines was decreased by 52% when cells were additionally treated with imatinib while ATF4 expression roughly remained unchanged in HL60 cells (Fig. 3b).